X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ASP-001 (sildenafil citrate oral spray) is a PDE-5 inhibitor, administered via a spray pump, which is being investigated for the treatment of erectile dysfunction.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: ASP-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
Sildenafil oral suspension is an oral liquid suspension of sildenafil citrate administered via a metered-dose pump that dispenses 12.5 mg of sildenafil per actuation act as phosphodiesterase-5 inhibitor, which being investigated for the treatment of erectile dysfunction.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: ASP-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
ASP-001 (sildenafil citrate oral spray) is a PDE-5 inhibitor, administered via a spray pump, which is being investigated for the treatment of erectile dysfunction.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: ASP-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Details:
ASP-001 (sildenafil citrate oral spray) is a PDE-5 inhibitor, administered via a spray pump, which is being investigated for the treatment of erectile dysfunction.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: ASP-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
Hezkue (sildenafil), inhibits cGMP-specific PDE-5. Penile erection involves corpus cavernosum relaxation, mediated by NO and cGMP. The biological actions of cGMP are terminated by phosphodiesterase enzymes and PDE-5 is the major cGMP metabolising enzyme in this tissue.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: Hezkue
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
The license grants Taiba the exclusive right and license to market, promote, and distribute Viagra as Sildenafil Spray in the territory described in the license, which covers Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, Oman, Lebanon, Egypt, and Iraq.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: Viagra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Taiba Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 04, 2022
Details:
Sildenafil oral spray is an oral liquid suspension of sildenafil citrate administered via a spray pump that dispenses 12.5 mg of sildenafil per push. The discreet and easy-to-carry oral spray allows the user to customize dosing and avoid pill splitting tablet medication.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Vanquish Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 21, 2022
Details:
BANDOL®, offered in a convenient and discreet metered dose container that delivers the equivalent of 12.5 mg of Sildenafil per actuation, is manufactured in Spain and is prescribed predominantly by primary care physicians and urologists.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Psychiatry/Psychology Product Name: Bandol
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Rubio Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 04, 2022
Details:
Aspargo’s Sildenafil Oral Spray is an oral liquid suspension of sildenafil citrate administered via a spray pump that dispenses 12.5 mg of sildenafil citrate per push of the pump (referred to as ASP-001) or via an individual single liquid unit dispensing 100 mg per unit.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Endocrinology Product Name: Viagra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Farmalider SA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 29, 2020
Details:
FDA supported Aspargo’s plan to conduct a single dose bioequivalent study to assess the pharmacokinetics, bioequivalency, tolerability and safety of the Company’s Sildenafil Oral Spray drug candidate.
Lead Product(s): Sildenafil Citrate
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
